Status:

UNKNOWN

The Effect of Ibuprofen on Women With PCOS.

Lead Sponsor:

Poznan University of Medical Sciences

Conditions:

PCOS

Hyperandrogenism

Eligibility:

FEMALE

18-40 years

Phase:

PHASE2

Brief Summary

Polycystic ovary syndrome occurs in about 10% of women of childbearing age. His pathogenesis is not fully understood. More and more research concerns the role of chronic inflammation in these women as...

Detailed Description

Polycystic ovary syndrome 1 is diagnosed in about 4-8% of women of childbearing age and is,therefore one of the most common endocrinopathies. The exact pathogenetic mechanism of PCOS is not fully disc...

Eligibility Criteria

Inclusion

  • Inclusion Criteria (patient should meet all the criteria)
  • Diagnosis of PCOS according to Rotterdam Criteria
  • Written consent to participate in a clinical trial
  • Age up to 40 years
  • Irregular periods (\> 35 days) or secondary amenorrhea over 3 months
  • Hyperandrogenism (hirsutism and / or acne) and / or total serum testosterone\> 0.5 ng / mL
  • Exclusion Criteria:
  • A diagnosed chronic disease, including in particular:
  • Cancer of the ovary, adrenal gland, endometrium, cervix, mammary gland
  • Congenital adrenal hyperplasia (17-OH- progesterone\> 2 ng / mL)
  • Clinically diagnosed Cushing's disease, acromegaly, gigantism
  • Type I or II diabetes
  • Gastrointestinal diseases (peptic ulcer, inflammatory bowel disease, liver disease)
  • Active or history of gastric and duodenal ulceration, perforation or bleeding, also following NSAIDs. Gastrointestinal bleeding
  • Severe hepatic impairment, severe renal insufficiency or severe heart failure.
  • Hemorrhagic diathesis.
  • systemic lupus erythematosus and mixed connective tissue disease
  • a history of hypertension and cardiac dysfunction
  • kidney problems
  • Unexplained vaginal bleeding
  • Use of hormonal treatment currently or during the last 2 months
  • Unexplained abdominal pain
  • Chronic use of drugs, especially: lithium salts, warfarin, oral hypoglycaemics, contraceptives, methotrexate, drugs that lower blood pressure, ACE inhibitors, b-blockers, diuretics that may cause interactions with ibuprofen, corticosteroids, mifepristone,
  • Hypersensitivity to ibuprofen or any of the excipients.
  • Existing or past allergy symptoms in the form of a runny nose, urticaria or bronchial asthma after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs., Cyclosporin, quinoline antibiotics
  • Pregnancy and lactation
  • Concomitant use of other nonsteroidal anti-inflammatory drugs, including selective COX-2 inhibitors (increased risk of side effects).

Exclusion

    Key Trial Info

    Start Date :

    September 1 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2021

    Estimated Enrollment :

    20 Patients enrolled

    Trial Details

    Trial ID

    NCT04485403

    Start Date

    September 1 2019

    End Date

    December 1 2021

    Last Update

    July 24 2020

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Division of Infertility and Reproductive Endocrinology, Department of Gynecology and Obsterics

    Poznan, Greater Poland Voivodeship, Poland, 60-535